Personalized Intervention to Improve Medication Adherence for Persons with Multiple Sclerosis
Efrat Neter,Efrat Esterkin-Hubner,Lea Glass-Marmor,Anat Wolkowitz,Idit Lavi,Ariel Miller
DOI: https://doi.org/10.2147/ppa.s455518
2024-06-13
Patient Preference and Adherence
Abstract:Efrat Neter, 1 Efrat Esterkin-Hubner, 2 Lea Glass-Marmor, 2 Anat Wolkowitz, 2 Idit Lavi 3 , † Ariel Miller 2, 4 1 Ruppin Academic Center, Emeq Hefer, Israel; 2 Multiple Sclerosis Center & Department of Neurology,Carmel Medical Center, Haifa, Israel; 3 Department of Community Medicine & Epidemiology, Carmel Medical Center, Haifa, Israel; 4 Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel †Idit Lavi passed away on 31.7.2022 Correspondence: Efrat Neter, Ruppin Academic Center, 3 Bait, Emeq Hefer, 4025000, Israel, Tel +972-54-6462677, Fax +972-9-8983043, Email ; Purpose: To evaluate the acceptability, retention, and efficacy of face-to-face intervention, incorporating education and Motivational Interviewing (MI) to support persons with relapsing-remitting multiple sclerosis (PwRRMS) and increase self-reported medication adherence. Patients and Methods: PwRRMS (N = 60) prescribed Disease Modifying Treatment (DMT), who were identified as non-adherent and consented to participate in an intervention, received verbal education and counseling from their treating physician, a tailored MI counseling and a booster session via telephone with a health psychologist, and a concluding MI counseling six months later. Each PwRRMS filled a battery of patient-reported outcomes (PROs) at baseline, six and 12 months later. The design was a quasi-experimental pre-test post-test across a year. Results: Of the sixty identified persons who consented to enroll, 52 completed the intervention and 46 completed the follow-up. At six months following the baseline, adherence scores increased (median = 12.0) and were significantly different than at baseline (median=10.0, p = 0.030). Still, at 12 months follow-up there was no significant difference from baseline in reported adherence (median = 11.0, p = 0.106). Conclusion: This study demonstrated reasonable retention and initial efficacy of a combined psycho-education and MI protocol for PwRRMS to enhance medication adherence to DMT. To maintain the change, a more sustained intervention is required. Plain Language Summary: The study focused on persons with relapsing-remitting multiple sclerosis (PwRRMS) who do not adhere to their prescribed medication. Following the identification of non-adherent persons, PwRRMS were offered an intervention to increase their adherence. The study examined how many of those identified consented to enroll in the intervention, how many remained in the intervention, and whether the intervention was efficacious in terms of self-reported adherence. The intervention included verbal education and counseling from the treating physician, immediately followed by tailored counseling by a psychologist. There was a booster session via telephone with the psychologist, and a concluding counseling meeting six months later. Participants were followed for a year after the initial counseling. Two-thirds of PWMS identified as non-adherent consented to enroll (n = 60), 52 completed the intervention and 46 completed the follow-up. At six months following counseling, self-reported adherence scores significantly increased, but at 12 months follow-up there was no significant difference from baseline in reported adherence. To maintain the change, a more sustained intervention is required. Keywords: disease modifying therapy, medication adherence, medication beliefs, motivational interviewing, multiple sclerosis, participatory medicine, patient reported outcomes Disease-modifying therapies (DMTs), currently a mainstay of treatment strategies for persons with relapsing-remitting multiple sclerosis (PwRRMS), have been shown to limit the number of relapses, prevent new lesion formation, as well as reduce the accumulation of disability. 1 Adherence to DMT has also been associated with improved quality of life, a decrease in neuropsychological issues and fewer days of work loss. 2,3 Alongside, adherence to DMT also reduces hospitalizations, emergency visits, and outpatient visits, also manifested in reduced annual medical care costs at the societal level. 4,5 Adherence is especially important in chronic conditions, and more so when disease onset is at an early age, requiring many years of treatment. Despite the above benefits, there are specific challenges to consistent DMT use. While the need for DMT may not seem clear in times of disease inactivity or mild course, as disease progression is unnoticeable to PwRRMS, 6 the costs of medication taking is prevalent: PwRRMS report on many adverse side effects 6,7 which are a main component of satisfaction with me -Abstract Truncated-
medicine, general & internal